ArticleNature communications2017
In vivo transplantation of 3D encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bioengineering trends in female reproduction: a systematic review.Human reproduction update · 2022Pooled it
- Review
- Bioengineering Ovarian Endocrine Function: From Follicle Modeling to Cell-Based Hormone Therapy.Advanced healthcare materials · 2026Review
- Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives.Bioengineering & translational medicine · 2026Review
- Biomaterials for Reproductive Restoration: Translating Engineering Innovations.Biomaterials research · 2026Review
- Bioengineered ovary reconstructs follicle-like structures in a mouse model of chemotherapy-induced premature ovarian failure.Stem cell research & therapy · 2025Article
- Development and Applications of Organoids in Gynecological Diseases.Stem cell reviews and reports · 2025Review
- Multi-cellular engineered living systems to assess reproductive toxicology.Reproductive toxicology (Elmsford, N.Y.) · 2024Review
- A Simple Mathematical Model Demonstrates the Potential for Cell-Based Hormone Therapy to Address Dysregulation of the Hypothalamus-Pituitary-Ovary Axis in Females with Loss of Ovarian Function.Annals of biomedical engineering · 2024Article
- Injectable Biomimetic Hydrogel Constructs for Cell-Based Menopausal Hormone Therapy with Reduced Breast Cancer Potential.Biomaterials research · 2024Article
- Artificial ovaries constructed from biodegradable chitin-based hydrogels with the ability to restore ovarian endocrine function and alleviate osteoporosis in ovariectomized mice.Reproductive biology and endocrinology : RB&E · 2023Article
- Design and Application Strategies of Natural Polymer Biomaterials in Artificial Ovaries.Annals of biomedical engineering · 2023Review
- Roadmap on biomaterials for women's health.JPhys materials · 2023Article
- Biomaterials and advanced technologies for the evaluation and treatment of ovarian aging.Journal of nanobiotechnology · 2022Review
- Biomaterial strategies for the application of reproductive tissue engineering.Bioactive materials · 2022Review
- Ovarian Tissue-Based Hormone Replacement Therapy Recovers Menopause-Related Signs in Mice.Yonsei medical journal · 2022Article
- An optogenetic approach for regulating human parathyroid hormone secretion.Nature communications · 2022Article
- Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy.Bioactive materials · 2021Review
- Regenerative Medicine Approaches in Bioengineering Female Reproductive Tissues.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Recent Advancements in Engineered Biomaterials for the Regeneration of Female Reproductive Organs.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Safe clinical hormone replacement (HR) will likely become increasingly important in the growing populations of aged women and cancer patients undergoing treatments that ablate the ovaries. Cell-based HRT (cHRT) is an alternative approach that may allow certain physiological outcomes to be achieved with lower circulating hormone levels than pharmacological means due to participation of cells in the hypothalamus-pituitary-ovary feedback control loop. Here we describe the in vivo performance of 3D bioengineered ovarian constructs that recapitulate native cell-cell interactions between ovarian granulosa and theca cells as an approach to cHRT. The constructs are fabricated using either Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.